Immunis, Inc., a clinical-stage biotech firm developing multi-active stem cell-derived biologics targeting age-related immune dysregulation, has been named one of the “Top 25 Biotech & Life Sciences Companies for 2025” by The Healthcare Technology Report, according to the company.
This recognition, highly regarded among corporate executives, institutional investors, and industry leaders, affirms Immunis’ growing standing in biomedical innovation. The company said that the award reflects the ingenuity of its investigational secretome therapy, IMM01-STEM, which is designed to address age-related muscle atrophy—a condition estimated to affect all humans.
The Healthcare Technology Report, which selected Immunis following an intensive evaluation, assesses candidates based on product innovation, leadership, strategic impact, and contributions to the global advancement of patient healthcare. According to the company, IMM01-STEM represents the most clinically advanced secretome therapy worldwide and targets a major health challenge for which no pharmaceutical cure currently exists.
This accolade places Immunis among the industry’s most influential biotechnology companies advancing patient-centered innovation and underscores its commitment to regenerative therapeutic development.
